First-Generation Antihistamines and Seizures in Young Children
Frank Max Charles Besag
DOI: https://doi.org/10.1001/jamanetworkopen.2024.30295
2024-09-01
JAMA Network Open
Abstract:In JAMA Network Open , Kim et al 1 have reported an association between first-generation antihistamines and seizures in children from the age of 6 months, using a case-crossover approach in which participants act as their own controls. This nationwide Korean study identified 11 729 eligible children, of whom 3178 were "discordant" (ie, exposed to antihistamines in the period before a seizure or during the control period, but not both), suggesting an increased seizure risk with the antihistamines. The report by Kim et al 1 is interesting from several points of view. First, most clinicians would probably not view antihistamines as increasing seizure risk, with the possible exception of febrile seizures, for which there have been reports of decreased duration between fever occurrence and seizure onset and longer duration of the seizure. 2 ,3 However, the present study specifically excluded febrile seizures. The authors have also adjusted their odds ratios (AORs) for several potentially confounding factors. Second, although it provides convincing evidence for a statistically significant increased seizure risk, specifically in children aged 6 to 24 months (AOR, 1.49 [95% CI, 1.31-1.70), but not for those aged 25 months to 6 years (AOR, 1.11 [95% CI, 1.00-1.24) or those 7 years and older (AOR, 1.10 [95% CI, 0.94-1.28]), it could be argued that these results pose more questions than they provide answers for the practicing clinician. Some of the questions might include the following: How should a relatively small risk translate into clinical practice? What do the mean results of this study imply for the individual child? In particular, are there any additional individual risk factors that should be taken into account? Is the effect dose related, against the background of clear dose- and blood-level–related increased seizure risk with other medications, such as the classical reports of seizure risk with imipramine 4 and the data suggesting that the seizure risk even with clozapine appears to be blood-level related? 5 Are the newer antihistamines associated with lower seizure risk, and should they be chosen in preference to the first-generation antihistamines? Should antihistamines be avoided altogether in younger children because of the small seizure risk associated with first-generation antihistamines? For those children who did have seizures, did the association appear to be with single seizures only or with an increased risk of epilepsy? Because seizures (specifically febrile seizures) are common in children younger than 5 years, 6 how seriously should a single brief seizure occurrence be viewed? Were there any cases of status epilepticus, which is clearly a serious and potentially brain-damaging condition, reported in association with first-generation antihistamines? Despite the efforts made by the authors, was adequate adjustment made for all the confounding factors, including confounding by indication? Kim et al 1 have drawn attention to the fact that antihistamines are frequently prescribed for common-cold symptoms or for minor sedation. It might be difficult to justify prescription for such apparently trivial indications, in the light of the results of this study suggesting increased seizure risk. Although second-generation antihistamines are said to be less likely to cross the blood-brain barrier and consequently perhaps less likely to precipitate seizures, 7 ,8 there is research suggesting that the second-generation antihistamine, desloratadine, is associated with new-onset seizures. 9 Against the background of a possible overreaction to past concerns about seizure precipitation with a number of medications, which have subsequently been shown to be associated with little or no seizure risk, 10 should we welcome a study such as this or should it be emphasized that more data are required before clinicians should consider changing their practice? Of course, although the authors are quite right in concluding that "the benefits and risks of antihistamine use should always be carefully considered, especially when prescribing H 1 antihistamines to vulnerable infants," 1 it remains unclear exactly what the risks are, implying that performing such a benefit-risk assessment still requires further information, if it is to be performed in a meaningful way. Taking all this into account, what should we conclude? It would be reasonable to inform families that at least 1 study has suggested a relatively small increase in the risk of seizures with first-generation antihistamines, adding that there are still too few data to draw any firm conclusions and also providing families with the information on what to do if the child were to have a seizure. Of course, clinicians should monitor all their patients for possible adverse effects -Abstract Truncated-
medicine, general & internal